Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas

Liver International

Volumn 25, Issue 6, 2005, Pages 1202-1208

  Foja, S ^a   Goldberg, M ^a   Schagdarsurengin, U ^b   Dammann, R ^b   Tannapfel, A ^c   Ballhausen, Wolfgang G ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cholangiocarcinoma; DNA methylation; Epigenetics; FHIT; RASSF1A

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; K RAS PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ISOLATION; DNA METHYLATION; EPIGENETICS; EXON; GENE LOCUS; GENE LOSS; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC CODE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ACID ANHYDRIDE HYDROLASES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DNA METHYLATION; EPIGENESIS, GENETIC; EXONS; GENE SILENCING; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); TUMOR SUPPRESSOR PROTEINS;

EID: 28944440361     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01174.x     Document Type: Article

References (31)

1. Yamanaka N, Okamoto E, Ando T, Oriyama T, Fujimoto J, Furukawa K, et al. Clinicopathologic spectrum of resected extraductal mass-forming intrahepatic cholangiocarcinoma. Cancer 1995; 76: 2449-56.
2. Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B. Surgical treatment of cholangiocellular carcinoma. World J Sing 1995; 19: 83-8.
3. Kang Y K, Kim W H, Lee H W, Lee H K, Kim Y I. Mutations of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999; 79: 77-83.
4. Tannapfel A, Engeland K, Weinans L, Katalinic A, Hauss J, Mossner J, et al. Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. Br J Cancer 1999; 80: 1069-74.
5. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47: 721-7.
6. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96: 8489-92.
7. Ishii H, Dumon K R, Vecchione A, Trapasso F, Mimori K, Alder H, et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001; 61: 1578-84.
8. Ohta M, Inoue H, Cotticelli M G, Kastury K, Baffa R, Palazzo J, et al. The human FHIT gene, spanning the chromosome 3p14.2 fragile site in renal carcinoma associated translocation breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-97.
9. Corbin S, Neilly M E, Espinosa R III, Davis E M, McKeithan T W, Le Beau M M. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors. Cancer Res 2002; 62: 3477-84.
10. Barnes L D, Garrison P N, Siprashvili Z, Guranowski A, Robinson A K, Ingram S W, et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′, 5‴-P1, P3-triphosphate hydrolases. Biochemistry 1996; 35: 11529-35.
11. Siprashvili Z, Sozzi G, Barnes L D, McCue P, Robinson A K, Eryomin V, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13771-6.
12. Shi Y, Zou M, Farid N R, Paterson M C. Association of FHIT (fragile histidine triad), a candidate tuniour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem J 2000; 352: 443-8.
13. Pekarsky Y, Garrison P N, Palamarchuk A, Zanesi N, Aqeilan R I, Huebner K, et al. Fhit is a physiological target of the protein kinase Src. Proc Natl Acad Sci USA 2004; 101: 3775-9.
14. Dammann R, Li C, Yoon J H, Chin P L, Bates S, Pfeifer G P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315-9.
15. Vos M D, Ellis C A, Bell A, Birrer M J, Clark G J. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000; 275: 35669-72.
16. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang X F, et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002; 12: 253-65.
17. Liu L, Tommasi S, Lee D H, Dammann R, Pfeifer G P. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003; 22: 8125-36.
18. Fenton S L, Dallol A, Agathanggelou A, Hesson L, Ahmed-Choudhury J, Baksh S, et al. Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res 2004; 64: 102-7.
19. Song M S, Song S J, Ayad N G, Chang J S, Lee J H, Hong H K, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004; 6: 129-37.
20. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe H H, Pfeifer G P, et al. Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003; 22: 1866-71.
21. Esteller M, Herman J G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196: 1-7.
22. Jones P A, Baylin S B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
23. Koch E, Fiedler W, Tannapfel A, Ballhausen W G. Alteration of the fragile histidine triad gene in intrahepatic cholangiocarcinoma. Eur J Gastroenterol Hepatol 2003; 15: 907-13.
24. Sobin LH, Wittekind C, eds. TNM, Classification of Malignant Tumors, 5th edn. New York, USA: Wiley-Liss, Inc, 1997.
25. Ishak T, ed. Histological Typing of Tumors of the Liver, 2nd edn. Berlin, Germany: Springer, 1994.
26. Hilgers W, Koerkamp B G, Geradts J, Tang D J, Yeo C J, Hruban R H, et al. Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas. Genes Chromosomes Cancer 2000; 27: 239-43.
27. Wistuba I I, Ashfaq R, Maitra A, Alvarez H, Riquelme E, Gazdar A F. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol 2002; 160: 2073-9.
28. Ishii H, Ozawa K, Furukawa Y. Alteration of the fragile histidine triad gene early in carcinogenesis: an update. J Exp Ther Oncol 2003; 3: 291-6.
29. Wong N, Li L, Bang K, Lai P B, To K F, Johnson P J. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002; 37: 633-9.
30. Van Engeland M, Roemen G M, Brink M, Pachen M M, Weijenberg M P, De Bruine A P, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002; 21: 3792-5.
31. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003; 22: 3806-12.